Claim · 2025-03-31 · announcement · Stated in source · Supported

Isomorphic Labs' 31 March 2025 release names Thrive Capital as the lead of its $600 million round.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Thrive Capital → participated in funding for → Isomorphic Labs

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Thrive Capitalparticipated in funding for ↓Isomorphic Labs

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2025-03-31 · announcement Records dated 2025 →
Stage: announced

Scope and limitsNamed participation as announced; the round total is not attributed to this investor and no individual amount is stated.

The evidence 01

primary sourceSupports the claim

Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic

Isomorphic Labs · 2025-03-31

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“The financing round is led by Thrive Capital, with participation from GV, and follow-on capital from existing investor, Alphabet.”

Location in source PDF p. 1, first paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Isomorphic Labs
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 e951f4f8ee6b24076c8112db8ee5eed3cb594218cc837305557e240389e43ac8). PDF news release dated LONDON, 31 March, 2025, linked from the Isomorphic Labs article of that date; retrieved 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Isomorphic Labs, “Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic”, 2025-03-31.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (19 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A28) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. Named participation in a financing round. The full round total is not attributed to this investor.

Date. Dated by the release.

Record ID aib-labs-thrive-iso-round-2025